A phase III comparison of radiation therapy with or without recombinant β-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04)
- 1 April 2002
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 52 (5) , 1173-1179
- https://doi.org/10.1016/s0360-3016(01)02797-3
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Interferon-β-1b (Betaseron®): A Model for Hydrophobic Therapeutic ProteinsPublished by Springer Nature ,2002
- Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non–small-cell lung cancer (LA-NSCLC): Identification of five groups with different survivalInternational Journal of Radiation Oncology*Biology*Physics, 2000
- How Interferons Fight DiseaseScientific American, 1994
- Combined betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancerInternational Journal of Radiation Oncology*Biology*Physics, 1993
- A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung CancerNew England Journal of Medicine, 1990
- Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy.Journal of Clinical Oncology, 1990
- The Long-Term Stability of Recombinant (Serine-17) Human Interferon-βJournal of Interferon Research, 1988
- Potency Stability of Recombinant (Serine-17) Human Interferon-βJournal of Interferon Research, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- On a Test of Whether one of Two Random Variables is Stochastically Larger than the OtherThe Annals of Mathematical Statistics, 1947